BioLineRx initiates Phase 2 trial in first line metastatic pancreatic cancer

BioLineRx announced the initiation of a randomized, investigator-initiated Phase 2 clinical trial in first line metastatic pancreatic cancer based on preliminary data from the single-arm pilot phase. The combination drug trial includes the investigational candidate motixafortide. Sponsored by Columbia University, the amended study will modify a single-arm trial whose original design called for expansion to an additional 30 patients if data from a pilot phase of 10 patients was encouraging. The amended randomized study will compare combination treatment with the company’s CXCR4 inhibitor, a PD-1 inhibitor, and chemotherapy to chemotherapy alone in a larger number of patients